British Journal of Pharmacy and Pharmaceutical Sciences
DOI: 10.32996/bjpps
Journal Homepage: www.al-kindipublisher.com/index.php/bjpps

BJPPS
AL-KINDI CENTER FOR RESEARCH AND DEVELOPMENT

| RESEARCH ARTICLE

Analyzing and Critically Evaluating the Problems of Antiviral Chemotherapy

Abdul Bari Hejran[1] ✉ Atiqullah Sarwari[2], Virendra Kumar Yadav[3], Mohammad Hassan Hassand[4] and Parwiz Niazi[5]

[1]Department of Biology, Faculty of Education, Helmand University, Helmand, AFGHANISTAN; Department of Biotechnology, faculty of Biology and Biotechnology, Al-Farabi Kazakh National University, Almaty 050040, KAZAKHSTAN

[2]Department of Biology, Faculty of Education, Helmand University, Helmand, AFGHANISTAN

[3]Marwadi University Research Center, Department of Microbiology, Faculty of Sciences, Marwadi University, Rajkot-360003, Gujarat, India.

[4]Department of Biology, Faculty of Education, Kandahar University, Kandahar, AFGHANISTAN

[5]Department of Biology, Faculty of Education, Kandahar University, Kandahar, AFGHANISTAN; Department of Plant Protection, Faculty of Agriculture, EGE University, İzmir, TURKEY

Corresponding Author: Abdul Bari Hejran; Parwiz Niazi, **E-mail**: abdulbari.hejran94@gmail.com; parwiz60@gmail.com

| ABSTRACT

Antiviral chemotherapy, an indispensable tool in combating viral infections, faces numerous challenges that often undermine its overall effectiveness and application. This review critically examines the multifaceted issues associated with antiviral chemotherapy, drawing on comprehensive data from NCBI, PubMed, and other reputable academic sources. The primary purpose of this research is to analyze and evaluate key problems such as the development of drug resistance, narrow therapeutic windows, limited spectrum of activity, toxicity, high costs, viral latency, and the complexities inherent in combination therapy. These challenges necessitate a delicate and strategic balance in the development, regulation, and application of antiviral drugs. The research methodology included an exhaustive review of peer-reviewed articles and clinical studies sourced from PubMed and NCBI databases, focusing on ten critical challenges in antiviral chemotherapy. The findings underscore the persistent issue of drug resistance, particularly in RNA viruses like HIV and hepatitis C, which demand ongoing innovation in antiviral drug design and implementation. Additionally, the analysis reveals the significant risks posed by the narrow therapeutic index of many antiviral drugs, which often increases the likelihood of adverse effects, thus limiting their safe and effective use. The study also highlights the formidable challenges posed by viral latency and the limited efficacy of current therapies against emerging and re-emerging viral threats. This research significantly contributes to the understanding of the inherent limitations in existing antiviral therapies and underscores the pressing need for more effective, accessible, and safe treatments. The practical significance lies in offering insights that could guide future research, clinical practice, and policy decisions, ultimately improving global health outcomes in the fight against viral diseases.

| KEYWORDS

Antiviral resistance, Therapeutic index, Viral latency, Drug toxicity, Combination therapy, Antiviral drug development and Viral infection management

| ARTICLE INFORMATION

ACCEPTED: 15 August 2024 **PUBLISHED:** 03 September 2024 **DOI:** 10.32996/bjpps.2024.1.1.1

1. Introduction

Antiviral resistance testing is a rapidly advancing discipline driven by the swift evolution of viruses, emergent technologies, and shifting pharmacological landscapes. The clinical approach to antiviral resistance testing is transitioning from phenotypic to

genotypic methodologies, and from Sanger sequencing to next-generation sequencing (NGS) techniques. These advancements introduce both new opportunities and challenges. As novel antiviral agents are developed with heightened genetic resistance barriers, or as emerging viral strains dominate, the relevance of certain tests may rapidly fluctuate (Wang et al., 2024). Phenotypic assays, historically the foundational tools in clinical practice, assess viral replication or host cell destruction. Traditional plaque counting, a labor-intensive method, has largely been supplanted by alternative indirect measures of viral replication or cell death. Sanger sequencing, once the standard for identifying resistance-conferring mutations in viral genomes, is now being eclipsed by more advanced methods. Genotypic antiviral resistance testing is increasingly adopting NGS methods, which offer several advantages: higher throughput, reduced manual labor for bioinformatic analysis, the capacity to simultaneously examine multiple, non-contiguous genomic regions, and potential cost efficiencies depending on batch processing. Additionally, NGS provides enhanced sensitivity for detecting low-level resistant subpopulations. However, the clinical significance of these low-level resistance mutations remains uncertain, particularly in terms of their impact on therapeutic outcomes Table 01 (Wang, 2024). Antiviral agents strategically target molecular networks and components involved in virus-host interactions. Virus-specific agents directly bind to viral proteins, whereas host-targeted agents modulate host cell factors to inhibit viral activity. Therapeutic approaches such as virus-neutralizing antibodies, CRISPR/Cas-based interventions, and interferons play critical roles in eradicating viruses (Ianevski et al., 2022), safeguarding against bacterial invasions, and initiating robust antiviral immune responses (Ianevski et al., 2022). Antiviral agents are being employed with growing frequency to combat viral infections, notwithstanding the therapeutic complexities and potential nephrotoxicity associated with their use (Bule, Khan, & Niaz, 2019) (Bule et al., 2019). Drug resistance poses a significant threat to global public health, jeopardizing the effectiveness of treatments for infections, surgical procedures, cancer therapies, and immunosuppressive interventions (Jamrozik & Selgelid, 2020), and calls for urgent and coordinated responses to mitigate its impact (Jamrozik & Selgelid, 2020; Du et al., 2024). For instance; Influenza, which impacts approximately 1 billion individuals each year, results in an estimated 290,000 to 650,000 fatalities. The most vulnerable populations include young children and those with compromised immune systems (Lampejo, 2020). The emergence of significant resistance to adamantane therapy and neuraminidase inhibitors has rendered these treatments ineffective, leading to their discontinuation as recommended options (Lampejo, 2020). Harada et al. (2020) documented a case where a 49-year-old male patient, diagnosed with peramivir-resistant influenza A/H3N2, was administered baloxavir marboxil treatment despite the presence of a dual E119D/R292K neuraminidase mutation (Harada et al., 2020).

Kiso et al. (2023) discuss that while Nirmatrelvir, an oral antiviral, is effective against SARS-CoV-2 infection, resistance remains a pressing public health concern. Amino acid substitutions lead to reduced susceptibility, yet mutant strains with diminished sensitivity have not become dominant (Kiso et al., 2023; Yamamoto et al., 2024, Nie et al., 2022, Formiga et al., 2021). Iketani et al. (2023) indicate that SARS-CoV-2 can acquire resistance to nirmatrelvir through various pathways in vitro, with the E166V mutation demonstrating the most potent resistance (Iketani et al., 2023; Ip et al., 2023, Zhu et al., 2024). And In China, research has revealed that genotype C exhibited a higher incidence of potential NA resistance mutations compared to genotype B (Zhang et al., 2019), especially in patients experiencing virological breakthrough, notably tenofovir resistance, indicating possible clinical ramifications for antiviral treatment strategies (Zhang et al., 2019). And the same time; the rtA186T and rtI163V substitutions associated with entecavir resistance in Chinese patients were correlated with virological breakthrough or suboptimal response to entecavir therapy (Liu et al., 2019). This emergent pattern of ETV resistance mutations has been validated across several cases (Liu et al., 2019). And Gohar et al. (2023) reveal that prolonged exposure to hepatitis B virus therapy results in mutations within the HBV DNA polymerase gene, leading to drug resistance in 22.5% of patients in a study conducted in Pakistan (Gohar et al., 2023; Liu et al., 2019, Du et al., 2024).

Antiviral therapy can engender drug resistance, influenced by a myriad of factors that govern mutation prevalence and clinical ramifications (Mason et al., 2018). Unlike acute infections such as influenza and respiratory syncytial virus, resistance mutations are more prevalent in chronic infections, including HIV, HCV, and HBV. These resistance mutations significantly affect the formulation of therapeutic strategies, revision of treatment protocols, structuring of clinical trials, and the monitoring, reporting, and interpretation of resistance (Mason et al., 2018; Zhang et al., 2023, Wyles & Luetkemeyer, 2017, Du et al., 2024). And Investigators have identified intricate patterns of segment linkage, reassortment, and natural selection within the intrahost dynamics of antiviral resistance in the influenza A virus (Rogers et al., 2015). Utilizing single-molecule sequencing, the study revealed that individual resistance mutations emerged weeks prior to achieving dominance, evolved autonomously, and were assembled into novel combinations through reassortment (Rogers et al., 2015). And Shao et al. (2021) demonstrate that various drug-resistant HBV mutations may contribute to inadequate responses to adefovir plus entecavir in patients with pre-existing entecavir resistance. The study identified a novel multi-drug resistant HBV strain, and tenofovir-based rescue therapy was found to be effective for cases refractory to previous treatments (Shao et al., 2021). In summary; Clutter et al. (2016) report that while the global increase in antiretroviral therapy (ART) has significantly reduced HIV-1 mortality rates, the rise of HIV drug resistance (HIVDR) poses a substantial threat to the long-term success of ART and the goal of eliminating AIDS by 2030. Their findings underscore the necessity of a comprehensive understanding of HIVDR's genetic mechanisms, epidemiology, and management to develop effective

surveillance systems, treatment protocols, and case management strategies. In response, the World Health Organization has recommended the immediate initiation of treatment and pre-exposure prophylaxis for individuals at high risk (Clutter et al., 2016).

Table 01: Detailed Assessment of Challenges and Strategic Considerations in Antiviral Chemotherapy.

Parameters	Comments	Pros	Cons	Reference	Rule	Targets	Usage	Future Prospects
Drug Resistance	Occurs when viruses mutate, reducing drug effectiveness.	Drives innovation in antiviral development.	Leads to reduced efficacy and increased disease burden.	Rabaan et al. (2020)	Continuous monitoring of mutations and adaptive therapies.	HIV, Hepatitis B, Influenza D	Routine clinical use, especially in chronic viral infections.	Development of new drugs targeting specific resistance mechanisms.
Toxicity and Side Effects	Antiviral drugs can have severe side effects, especially in prolonged use.	Some drugs are effective with manageable toxicity.	Limits the use of highly effective drugs, leading to patient non-compliance.	Kumari et al. (2020)	Usage should be guided by risk-benefit analysis.	Immunocompromised patients, organ transplant recipients.	Prophylactic treatment in high-risk groups, long-term management in chronic infections.	Reducing side effects through more targeted therapies and personalized medicine.
Cost of Therapy	Antiviral therapy is often expensive, especially for newer drugs.	Increased accessibility of drugs through generics and government programs.	High cost limits access in low-resource settings, contributing to health disparities.	Saegerman et al. (2021)	Governments and NGOs to subsidize antiviral therapies for underprivileged populations.	Low-income countries, marginalized communities.	National healthcare programs, global funding initiatives for antiviral therapy distribution.	Development of more affordable generics and alternative therapies.
Treatment Failures	Occurs due to improper drug use, resistance, or incomplete understanding of the disease's progression.	Highlights the need for comprehensive research and improved drug design.	Can lead to relapse, extended infections, and further resistance.	Hayakawa et al. (2020)	Strict adherence to treatment protocols and individualized care.	HIV, Hepatitis C, and emerging viral threats.	Clinical trials and routine practice for patients with incomplete response to existing therapies.	Advancements in next-gen antiviral drugs, targeting specific stages of viral life cycles.
Viral Evolution	Viruses adapt and evolve, presenting ongoing challenges to antiviral chemotherapy.	Encourages ongoing research and technological advancements.	Limits the long-term effectiveness of antiviral therapies.	Okda et al. (2020)	Developing flexible and adaptable antiviral therapies.	Zoonotic diseases, emerging viral infections (e.g., SARS-CoV-2, Influenza).	Research focus on rapidly mutating viruses, anticipating future outbreaks.	Creation of universal antivirals, which target viral mechanisms that are less prone

								to mutation.
Limited Spectrum of Activity	Antivirals often target specific viruses, limiting their scope.	Ensures precision in treating specific viral infections.	Narrow activity range leaves many viruses without effective treatments.	Trombetta et al. (2022)	Expanding the spectrum of antiviral activity by exploring new viral targets.	Emerging viruses, zoonotic diseases, pandemics.	Investigational therapies, clinical trials to broaden the spectrum of antiviral efficacy.	Discovery of broad-spectrum antivirals targeting multiple virus families.
Immunocompromised Populations	Vulnerable to drug-resistant strains and severe side effects.	Antiviral drugs offer life-saving benefits when effectively administered.	Higher risk of drug resistance and reduced drug efficacy.	Gulis et al. (2021)	Focus on patient-specific treatment plans and developing less toxic drugs for this population.	Patients undergoing chemotherapy, organ transplants, and people with HIV.	Increased reliance on antivirals in specialized care and outpatient treatments for immunocompromised patients.	Development of patient-specific antivirals, reducing toxicity and side effects for fragile populations.
Drug Interactions	Antivirals can interact with other medications, complicating treatment.	Advances understanding of how antivirals interact within the body.	Potential for severe side effects or treatment failures when combined with other drugs.	Yesilbag et al. (2022)	Close monitoring of drug interactions and usage, especially in polypharmacy patients.	Elderly patients, patients with multiple comorbidities.	Routine monitoring of antiviral therapy in patients with other ongoing treatments.	Improved pharmaceutical formulations that reduce the risk of drug-drug interactions.
Access to Treatment	Barriers exist in terms of both geographic and socioeconomic factors.	Government initiatives can improve access.	Inaccessibility in remote and low-income regions persists.	Nogales et al. (2019)	Global collaboration and policies for fair distribution of antiviral drugs.	Rural areas, conflict zones, developing nations.	Global initiatives such as GAVI and WHO programs, expansion of healthcare systems to reach remote areas.	Innovations in distribution systems, new delivery mechanisms to ensure worldwide access.
Research and Development Lag	Long research and development cycles hinder rapid response to emerging threats.	Encourages collaboration and funding for rapid drug development.	May leave gaps in the treatment of new or mutated viruses during outbreaks.	Nuwarda et al. (2021)	Increased funding for accelerated research, regulatory approval processes.	Pandemics, zoonotic diseases, rapidly mutating viruses (e.g., Influenza, SARS-CoV-2).	Utilization of emergency-use authorizations during pandemics and fast-tracked clinical trials.	Rapid development platforms such as mRNA technology for antivirals, reducing the gap in

								response time.
Ethical Concerns in Trials	Ethical dilemmas arise in antiviral research, especially in vulnerable populations.	Necessary for the development of life-saving drugs.	Ethical concerns can delay trials, prolonging the approval process.	Gaudino et al. (2021)	Ethical guidelines must be strictly followed, including informed consent and protection of vulnerable groups.	Human subjects in clinical trials, especially children, pregnant women, and the immunocompromised.	Adherence to international standards for clinical trials and ensuring ethical transparency.	Development of better ethical frameworks that protect participants while ensuring rapid drug development.

2. Methodology

In this review, a comprehensive analysis was conducted by gathering data from reputable academic sources, including NCBI, PMD, and other reliable databases. The collected information was critically evaluated to identify and examine the existing problems in antiviral chemotherapy. The methodology focused on synthesizing recent research findings, emphasizing the challenges and limitations within the field, and ensuring a thorough and objective assessment of the available literature.

3. Results and Discussion

Drug resistance presents a formidable challenge to contemporary medicine, undermining the durability of therapeutic agents and constraining treatment alternatives. This issue is prevalent across various domains, including oncology, infectious diseases, agriculture, and cancer therapy (Kurt Yilmaz & Schiffer, 2021). Pathogens acquire resistance to antimicrobials, exacerbating the overreliance on herbicides and complicating cancer and infectious disease management. Addressing resistance necessitates a deep comprehension of molecular mechanisms, identification of weaknesses in existing drugs, and the development of innovative strategies. 'Chemical Reviews on Drug Resistance' employs structure-based drug design approaches for direct-acting antivirals and small-molecule cancer therapies. Additionally, advanced biomedical engineering techniques are imperative to surmount drug resistance challenges in oncology (Kurt Yilmaz & Schiffer, 2021). And Fitzsimmons et al. (2018) discovered that RNA viruses' exhibit elevated mutation rates as a result of selective pressure favoring enhanced replicative velocity. The 3DG64S poliovirus antimutator demonstrates a pronounced replication defect while maintaining comparable adaptability across two cellular environments. Their findings indicate that replication speed is prioritized over accuracy in RNA virus mutation rates, suggesting that viruses favor rapid replication at the expense of genetic fidelity (Fitzsimmons et al., 2018; Taroncher-Oldenburg et al., 2021, Li et al., 2024). And Duffy (2018) highlights that RNA viruses exhibit exceptionally high mutation rates, reaching up to a million times greater than those of their hosts, which correlates with increased virulence and adaptability. Nonetheless, these mutation rates are perilously elevated, and even a modest increase can lead to local extinction of RNA viruses. While researchers frequently posit that natural selection has fine-tuned the mutation rates of RNA viruses, recent data reveal that the selective pressure for accelerated replication is more pronounced in poliovirus, with faster polymerases consequently generating a greater number of errors. Mutations serve as the fundamental components of evolution, capable of responding to selective pressures (Duffy et al., 2018; Smith et al., 2017, Li et al., 2024). And "Goto et al. (2022) examined 2,472,725 scientific articles from PubMed Central to elucidate viral drug resistance. They identified mutational hotspots specific to each HBV genotype and gene, mapped disulfide bonds associated with these mutations, and highlighted a mutation site commonly found in clinical data and literature. This approach shows promise for advancing the development of more effective HBV therapeutics, as recent nucleotide analogues such as entecavir and tenofovir disoproxil have markedly reduced the incidence of resistance (Goto et al., 2022).

a. **Resistance as an Evolutionary Event:** Viral evolution, crucial for public health, is increasingly analyzed through population genetics, with real-time tracking of metrics like nucleotide diversity and selection strength aiding treatment decisions. Advances in molecular data reveal new mutations, especially those conferring drug resistance. Antiviral treatments, which target viral replication, face challenges as ineffective therapies can lead to rapid resistance due to high mutation rates and large viral populations, prompting continuous innovation in drug development.
b. **Diversity in Viral Biology and Resistance Mechanisms:** Differences in viral replication drive the development of new drug classes targeting various stages of the viral lifecycle. Understanding these differences is key for creating effective drugs and anticipating resistance. This summary covers resistance mechanisms in HCV, IAV, HSV, HCMV, HIV, and HBV, noting HCV's high mutation rate and IAV's rapid evolution due to selective pressure on surface proteins.

c. **Deducing Population Genetic Parameters in Viruses:** Accurately interpreting genetic parameters such as effective population size (Ne) requires a deep understanding of viral biology, as different methods and models can significantly affect estimates. Effective population size may vary based on intra-host or global populations, genome-wide or specific regions, and short or long time scales. The use of multiple merger coalescent models is increasingly important for precise analysis, and the type of recombination event can influence interpretations. Additionally, the impact of latent virus copies on these parameters is still debated. Hence, while parameter evaluation is best done on a case-by-case basis, generalizing across viruses can provide valuable insights, and more standardized measurement procedures would greatly advance the field.

d. **Genetic Barriers to Resistance:** The genetic barrier to resistance, which refers to the number and type of mutations required for resistance, varies with antiviral targets and drug classes. Older drugs often have low genetic barriers, needing only one or two mutations for resistance to emerge, while newer drugs aim to increase this barrier to reduce the likelihood of resistance. Resistance mutation rates are influenced by how many substitutions are required; simpler pathways to resistance are more common. For instance, in HCV, the R155K mutation needs a single nucleotide change in genotype 1a but two in genotype 1b, where it is less frequent. The genetic barrier also includes the mutation type, with transitions generally being more common than transversions. Fisher's geometric model helps conceptualize these mutations as adaptive walks, where new mutations might bring the phenotype closer to, maintain, or move it further from the optimum, with beneficial mutations being rarer. Thus, resistance is more likely to develop through fewer mutations rather than multiple steps, highlighting the importance of exploring potential mutation paths to anticipate and mitigate resistance. This approach can guide the development of antiviral drugs by identifying which viral traits to target to minimize rapid resistance, though incorporating additional factors, like the genetic code, may be necessary (Irwin et al., 2016, Vincenti et al., 2017, Hughes et al., 2015).

According to Wang and Tang (2016) discuss how the prolonged administration of nucleos(t)ide analogues (NAs) for chronic hepatitis B (CHB) has led to drug resistance and mutations within the reverse transcriptionase (RT) region of the HBV polymerase gene. These mutations, particularly involving truncated S proteins, impair virion secretion, retention of HBV surface proteins, and reduce serum HBV DNA levels. HBV infection affects approximately 2 billion individuals globally, causing 600,000-1,200,000 deaths annually. Although antiviral therapy with NAs has made significant progress in suppressing HBV replication with minimal adverse effects, extended use can diminish their antiviral efficacy over time (Wang et al., 2016). And Tamargo, Le Heuzey, and Mabo (2015) explain that the therapeutic index (TI) signifies the dosage range within which a drug is effective and safe, without inducing adverse effects. Non-Transforming Antibodies (NTIDs) possess a narrow margin between therapeutic and toxic doses. Generic medications can replace branded versions if they meet bioequivalence (BE) standards. Flecainide, an antiarrhythmic drug, is considered an NTID due to its steep dose-response curve, the requirement for therapeutic drug monitoring, and the variability in its pharmacokinetic (PK) properties among individuals. To ensure its safe use, it is vital to understand the risk of proarrhythmic effects, select patients carefully, and perform regular monitoring (Tamargo et al., 2015). And Kolakowska et al. (2019) investigate the adverse effects linked to HIV Integrase Inhibitors (INSTIs), particularly focusing on neuropsychiatric complications and weight gain. The study underscores the need for caution in patients with low eGFR and severe neuropsychiatric conditions, while advocating for the use of pharmacogenetics as a promising tool for tailored therapy (Kolakowska et al., 2019; Treisman et al., 2016).

3.1 Neuropsychiatric Impact of Antiviral Medications:

Antiviral drugs often cause dose-dependent, reversible neuropsychiatric side effects, ranging from mild irritability to severe conditions like depression and psychosis, which may require discontinuation of treatment. These effects are linked to molecular targets such as g human monoamine oxidase-A (MAO-A) and serotonin receptors. Notable examples include oseltamivir, which may act as an MAO inhibitor, and efavirenz, which interacts with serotonin and GABA receptors. Other antivirals, like nucleoside reverse transcriptase inhibitors, can cause peripheral neuropathy, while interferons may induce depression. Clinicians need to be aware of these side effects to manage them effectively (Zareifopoulos et al., 2020).

3.2 Neuropsychiatric Effects of Antiviral Therapy: *Neuraminidase Inhibitors:*

Oseltamivir and zanamivir, neuraminidase inhibitors for influenza, shorten disease duration and alleviate symptoms but have been linked to various neuropsychiatric adverse events, including delusions, delirium, and suicidal ideation, particularly in studies from the USA, Spain, Japan, China, and South Korea. Oseltamivir phosphate (OP), which requires conversion to the active form oseltamivir carboxylate (OC), may also inhibit human monoamine oxidase-A (MAO-A), affecting excitatory behaviors. Despite warnings from the Japanese Ministry of Health and the FDA, no definitive causal link between oseltamivir and abnormal behaviors has been established. Zanamivir has not been associated with major neuropsychiatric effects.

3.3 Acyclovir and Derivatives:

In herpes and CMV treatment, acyclovir and its derivatives have been associated with neuropsychiatric symptoms like tremor and hallucinations, often linked to renal failure or concurrent neurotoxic drugs. Valacyclovir, an ester pro-drug of acyclovir, is absorbed more efficiently but has been associated with confusion and psychosis.

3.4 Foscarnet:

Foscarnet, used for refractory CMV infections, may cause severe hypocalcemia and neurological adverse effects.

3.5 Nucleoside Analogues in Hepatitis B Treatment:

In chronic hepatitis B treatment, nucleoside analogues such as lamivudine and telbivudine have been linked to myopathy and peripheral neuropathy, potentially due to mitochondrial DNA depletion. Entecavir has fewer neuropsychiatric effects.

3.6 Sofosbuvir in Hepatitis C Treatment:

Sofosbuvir-based regimens for hepatitis C may cause mild neurotoxicity, with symptoms like insomnia and fatigue.

3.7 HIV Treatment:

In HIV treatment, NRTIs like zidovudine and tenofovir disoproxil fumarate can cause peripheral neuropathy and myopathy, though tenofovir alafenamide shows a better safety profile. NNRTIs, particularly efavirenz, can induce significant psychiatric symptoms, including sleep disturbances and mood dysregulation, though tolerance often develops over time (Zareifopoulos et al., 2020; Huntjens et al., 2023). Narrow Therapeutic Index (NTI) medications are a contentious issue within clinical pharmacology, necessitating precise dose titration and vigilant monitoring to ensure therapeutic efficacy (Habet, 2021). And Generic drugs are prescribed to mitigate pharmaceutical costs, though their bioequivalence is not always assured due to the biocreep phenomenon (Gozzo, Caraci, & Drago, 2022). In Italy, Transparency Lists mandate automatic substitution with generics, yet this approach fails to address the intricacies of biocreep (Gozzo et al., 2022). And the research evaluates the therapeutic efficacy of two M2-S31N inhibitors, specifically engineered to target multidrug-resistant influenza A viruses (Ma, Zhang, & Wang, 2016). Findings indicate that these inhibitors present a more substantial genetic resistance barrier compared to amantadine and exhibit a synergistic interaction with oseltamivir, thereby proposing them as promising candidates for antiviral drug development (Ma et al., 2016; Musharrafieh et al., 2018, Wang et al., 2018, Musharrafieh et al., 2020). In contrast; the rise of pandemic-capable pathogens such as Ebola, Zika, MERS-CoV, SARS, and SARS-CoV-2 presents formidable health risks. While vaccines are indispensable, concerns regarding their safety and efficacy can impede their rapid deployment. Consequently, broad-spectrum antiviral agents, including nucleoside analogues (Geraghty, Aliota, & Bonnac, 2021), are vital for an expedited response. Despite their benefits, repurposing existing drugs remains critical for emergency scenarios, necessitating compounds with extensive antiviral activity Geraghty et al., 2021).

3.8 Tackling the specificity and adverse effects of antiviral nucleoside agents:

Feng (2018) emphasizes that nucleoside and nucleotide analogues are utilized in antiviral treatments for HIV, HBV, HCV, and influenza. However, elevated failure rates due to toxicity have led to recommendations for testing drug candidates in mitochondrial toxicity assays (Feng, 2018; Chawla et al., 2018, Nemčovičová et al., 2024, Mahajan et al., 2021). Mafirakureva et al. (2022) conducted a cost-effectiveness analysis of a pilot HCV screening and treatment intervention in Nairobi, Kenya. According to their study, "the intervention used an existing model of HIV and HCV transmission among current and former People Who Inject Drugs (PWID) to estimate the cost-effectiveness of screening and treatment." They found that the intervention was "highly cost-effective, with currently available cheaper drug prices, provided that directly-observed therapy (DOT) is not used and HCV disease care costs are considered." The intervention involved "blood samples for HCV antibodies, genotyping, and pre-treatment tests," with eligible clients receiving treatment with daclatasvir and sofosbuvir (86.4%) or ledipasvir and sofosbuvir (13.6%) in a drop-in center without DOT (Mafirakureva et al., 2022; Marquez et al., 2021, Lim et al., 2023, Nyberg et al., 2023, Ahmed et al., 2017, Jiang et al., 2021, Kaplan et al., 2022, Zala et al., 2020, Dawoud & Soliman, 2020). And concurrently; A study evaluating the cost-effectiveness of baloxavir marboxil compared to oseltamivir and no antiviral treatment for influenza management in the US concluded that baloxavir is a cost-effective option. Baloxavir, an oral, single-dose endonuclease inhibitor, significantly alleviates influenza symptoms, reduces viral shedding, and shortens the infectious period. It is approved for treating acute uncomplicated influenza in individuals aged 5 years and older, as well as those aged 12 years and older who are at high risk of complications. The study revealed that baloxavir offered an incremental cost-effectiveness ratio (ICER) of $7,909 per quality-adjusted life year (QALY) gained compared to oseltamivir and $591 per QALY gained compared to no antiviral treatment, both comfortably below the $20,000/QALY benchmark (Kommandantvold et al., 2024). And the research investigates the application of subscription-based models to enhance accessibility to high-value, high-cost medications, such as Direct Acting Antivirals (DAAs) for Hepatitis C treatment. It underscores the complexities involved in assessing state-sponsored subscription models and their broader impacts, particularly on Medicaid recipients and incarcerated individuals. According to Auty, Griffith, Shafer, Gee, and Conti (2022), DAAs, including Sovaldi, demonstrate the potential to cure over 90% of patients or effectively manage chronic HCV, thereby improving health outcomes and mitigating disease burden. Nonetheless, the high costs associated with these medications can conflict with societal objectives, as they may be prohibitively expensive and subject to state-imposed restrictions. Subscription models, implemented in two US states, offer a potential framework for public financing of high-value drugs, potentially advancing public health (Auty et al., 2022; Jiang et al., 2023, Douglass et al., 2018, Tai & Yu, 2024).

The HIV reservoir, traditionally comprising infected long-lived memory CD4+ T cells, has been expanded to include additional T cell subsets such as naive CD4+ T cells, T follicular helper (TFH) cells, and macrophages. Resting CD4+ T cells are the only cell type that consistently meets these criteria, with the majority of latent virus residing in memory phenotype cells. However, naive CD4+ T cells, stem memory T cells, and transitional memory CD4+ T cells are also considered to harbor latent infection. Understanding HIV latency is essential for grasping how the virus persists within host cellular DNA. The persistence of replication-competent virus in macrophages, naive T cells, and other cell types during long-term antiretroviral therapy (ART) remains a contentious issue. Identifying a host marker expressed in these cells could have a profound impact on the pursuit of a cure (Churchill et al., 2016 ; Xiang et al., 2018, Cohen, 2020, Lieberman, 2016, Speck & Ganem, 2010, Chou et al., 2024). In addition; a comprehensive systematic review and network meta-analysis encompassing 7,840 trials assessing Ebola virus treatments indicated that REGN-EB3 and mAb114 are likely to significantly decrease mortality compared to standard care. However, the confidence in the evidence supporting ZMapp and remdesivir's impact on mortality was deemed low or very low (Gao et al., 2022). The findings imply that healthcare professionals should prioritize these therapies in managing patients with Ebola virus disease in future outbreaks. Given that Ebola virus disease is a highly lethal acute infectious condition, early detection, vaccination, and supportive care are critical for improving survival rates. Additionally, the World Health Organization has convened an international guideline panel to address treatment strategies for Ebola virus disease (Gao et al., 2022; Iversen et al., 2020). And the inactivated Zika virus vaccine, which has shown potential in preventing maternal-fetal transmission and congenital Zika syndrome during pregnancy, demonstrates substantial efficacy (Kim et al., 2022). In studies with C57BL/6 mice, the vaccine notably diminished ZIKV-induced fetal malformations, and in marmosets, it effectively blocked the vertical transmission of ZIKV, showcasing robust and durable protective capabilities against adverse outcomes during pregnancy Kim et al., 2022; Wang et al., 2019).

3.9 Evaluating the Efficacy of Two Antiviral Treatment Regimens in COVID-19 Patients:

According to Mazaherpour et al. (2022), a study comparing the efficacy and side effects of atazanavir/ritonavir (ATV/r) and lopinavir/ritonavir (LPV/r) plus hydroxychloroquine in COVID-19 patients found no significant difference in clinical outcomes. The study involved 108 patients with moderate to severe COVID-19, divided into two groups. The ATV/r group exhibited a notable increase in bilirubin levels compared to the LPV/r group, which experienced a significant rise in arrhythmias. Despite these side effects—hyperbilirubinemia with atazanavir and arrhythmia with lopinavir—no substantial differences were observed in hospital stay length, overall outcomes, or treatment complications between the two antiviral combinations Mazaherpour et al., 2022; Chan et al., 2024).

3.10 Therapeutic strategies involving the combination of multiple drugs for the treatment of emerging viral infections:

Combination therapy has demonstrated considerable success in managing chronic viral infections such as HIV and HCV by diminishing viral load and reducing both morbidity and mortality. This approach also holds promise for enhancing therapeutic outcomes against emerging and re-emerging pathogens, including influenza, SARS-CoV, MERS-CoV, Ebola, Zika, and SARS-CoV-2. Utilizing drug repurposing screens can accelerate the identification of viable treatments for novel viral infections, as repurposed drugs may be rapidly integrated into clinical trials or emergency use. The efficacy of drug repurposing can be further augmented by pinpointing effective drug combinations with synergistic properties (Shyr et al., 2021). This therapeutic approach is also employed in treating a range of conditions, including cancer, hypertension, and severe bacterial or fungal infections. The use of polypills has proven effective in improving patient adherence and mitigating drug resistance. In essence, drug combination therapy offers a substantial enhancement in quality of life and longevity by boosting therapeutic effectiveness and preventing resistance development (Shyr et al., 2021; Batool et al., 2023). And the FDA has established expedited pathways, such as Emergency Use Authorization, to accelerate the availability of vaccines prior to full approval, allowing for a more flexible evidence requirement, including the use of surrogate markers for accelerated effectiveness evaluation. The importance of post-approval safety monitoring is underscored by mechanisms like the CDC and FDA Vaccine Adverse Event Reporting System, the CDC Vaccine Safety Datalink, and the CDC Clinical Immunization Safety Assessment Project. Balancing speed with thoroughness is essential for effective pandemic management. According to Kesselheim et al. (2021), the FDA Center for Biologics Evaluation and Research oversees vaccine approval and regulation, with three programs designed to expedite approval: fast track, breakthrough therapy, and accelerated approval (Kesselheim et al., 2021; Tompa et al., 2021, Ao et al., 2023, Meganck & Baric, 2021, Bak, Burlage, Greene, Nambiar, Lu, & Templeton, 2024). Approximately 400,000 children globally are diagnosed with cancer annually, and over 80% of these patients achieve long-term survival. The advancement of molecular techniques and targeted therapies has markedly improved survival rates and reduced the adverse effects associated with conventional chemotherapy. Current treatment modalities provide renewed hope for patients facing relapses or resistance to traditional treatments. However, ongoing research is essential to develop novel and more precise methods to further enhance survival rates among pediatric cancer patients. Immunotherapy has emerged as a promising approach to extend overall survival and disease-free intervals in pediatric patients with Philadelphia chromosome-positive (Ph+) or rearranged B-cell acute lymphoblastic leukemia (B-ALL). The introduction of chimeric antigen receptor (CAR) T-cell therapy has revolutionized pediatric oncology (Adamczewska-Wawrzynowicz et al., 2023 ; Nalwanga & Musiime, 2022, Penazzato et al., 2022, Lee et al., 2021, Valencia Deray, Danziger-Isakov, & Downes, 2024, (Shook & Lin, 2017). To conclude; the 20th century has experienced a significant rise in viral epidemics and pandemics, revealing the major global health

challenges associated with emerging pediatric viral diseases. This problem is intensified by several factors such as climate change, globalization, socio-economic interconnections, geopolitical conflicts, vaccine reluctance, misinformation, and inequalities in healthcare access. The critical need for effective prevention, preparedness, and response strategies, particularly in resource-poor regions, is clear. Adopting a One Health/Planetary Health framework could improve equity and resilience across global communities. A thorough understanding of viral disease trends and current global efforts is crucial for addressing this ongoing public health challenge (Hoffman & Maldonado, 2024).

4. Conclusion

This review meticulously investigates the intricate challenges associated with antiviral chemotherapy, with the aim of elucidating critical issues that compromise its efficacy. To achieve this, the study synthesizes data from a comprehensive array of peer-reviewed sources, including NCBI and PubMed. Key impediments addressed include drug resistance, narrow therapeutic windows, drug toxicity, financial constraints, and viral latency. The analysis reveals that, despite significant advancements, persistent barriers continue to impact the effectiveness of antiviral therapies. Specifically, the rapid emergence of drug-resistant viral strains, combined with the limited therapeutic margins of many antiviral agents, as well as the significant risk of adverse effects, are prominent issues. Furthermore, high costs associated with antiviral treatments and the challenges posed by viral latency and specificity further exacerbate the difficulties in managing viral infections. The study confirms that, although antiviral therapy has made notable progress, substantial obstacles remain. Drug resistance and narrow therapeutic indices are critical challenges that must be addressed through ongoing research and innovation. These limitations highlight the need for continued efforts to enhance the efficacy and safety of antiviral treatments. Moving forward, future research should focus on developing new antiviral agents with broader therapeutic spectra and improved safety profiles. Moreover, exploring alternative therapeutic strategies, alongside the implementation of advanced technologies and novel drug delivery systems, could provide significant benefits. Addressing these challenges is essential for advancing antiviral treatment and ultimately improving global health outcomes in the fight against viral diseases.

Funding: This research received no external funding.

Conflicts of Interest: The authors declare no conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers.

Highlights

- ***Drug Resistance:*** *Rapid viral mutations, especially in RNA viruses like HIV and hepatitis C, lead to drug-resistant strains, necessitating the continual development of new antiviral drugs.*
- ***Narrow Therapeutic Window:*** *Antiviral drugs often have a small margin between effective and toxic doses, increasing the risk of side effects and limiting safe dosage options.*
- ***Limited Spectrum of Activity:*** *Many antiviral agents target specific viruses, requiring precise diagnosis and limiting their usefulness against other viral infections.*
- ***Toxicity and Side Effects:*** *Significant side effects, such as organ toxicity and immune suppression, can affect patient compliance and lead to discontinuation of treatment.*
- ***High Cost and Accessibility:*** *The high cost of developing and producing antiviral drugs limits access, especially in low-income regions, hindering global treatment efforts.*
- ***Viral Latency and Reservoirs:*** *Some viruses, like HIV, can enter a latent state, evading detection and making them difficult to eradicate with current antiviral therapies.*
- ***Combination Therapy Challenges:*** *The need for combination therapies to prevent resistance can lead to complex drug interactions and increased toxicity, requiring careful management.*
- ***Barriers to Rapid Development and Approval:*** *The lengthy and costly process of developing and approving new antiviral drugs delays the availability of treatments for emerging viral threats.*
- ***Limited Efficacy for Certain Infections:*** *Some viral infections, such as Ebola and Zika, have limited or no effective antiviral treatments, highlighting the need for continued research.*
- ***Challenges in Pediatric and Special Populations:*** *Limited testing and approval of antiviral drugs for children, pregnant women, and immunocompromised individuals create gaps in treatment options for these vulnerable groups.*

References

[1] Adamczewska-Wawrzynowicz, K., Wiącek, A., Kozłowska, A., Mikosza, K., Szefler, L., Dudlik, W., Dey, S., Varghese, N., & Derwich, K. (2023). Modern treatment strategies in pediatric oncology and hematology. *Discover oncology*, *14*(1), 98. https://doi.org/10.1007/s12672-023-00658-7

[2] Ahmed, A., Gonzalez, S. A., Cholankeril, G., Perumpail, R. B., McGinnis, J., Saab, S., Beckerman, R., & Younossi, Z. M. (2017). Treatment of patients waitlisted for liver transplant with all-oral direct-acting antivirals is a cost-effective treatment strategy in the United States. *Hepatology (Baltimore, Md.)*, *66*(1), 46–56. https://doi.org/10.1002/hep.29137

[3] Ao, D., He, X., Liu, J., & Xu, L. (2023). Strategies for the development and approval of COVID-19 vaccines and therapeutics in the post-pandemic period. *Signal transduction and targeted therapy*, *8*(1), 466. https://doi.org/10.1038/s41392-023-01724-w

[4] Auty, S. G., Griffith, K. N., Shafer, P. R., Gee, R. E., & Conti, R. M. (2022). Improving Access to High-Value, High-Cost Medicines: The Use of Subscription Models to Treat Hepatitis C Using Direct-Acting Antivirals in the United States. *Journal of health politics, policy and law*, *47*(6), 691–708. https://doi.org/10.1215/03616878-10041121

[5] Bak, A., Burlage, R., Greene, N., Nambiar, P., Lu, X., & Templeton, A. (2024). Accelerating Drug Product Development and Approval: Early Development and Evaluation. *Pharmaceutical research*, *41*(1), 1–6. https://doi.org/10.1007/s11095-023-03566-1

[6] Batool, S., Chokkakula, S., & Song, M. S. (2023). Influenza Treatment: Limitations of Antiviral Therapy and Advantages of Drug Combination Therapy. *Microorganisms*, *11*(1), 183. https://doi.org/10.3390/microorganisms11010183

[7] Bule, M., Khan, F., & Niaz, K. (2019). Antivirals: Past, Present and Future. *Recent Advances in Animal Virology*, 425–446. https://doi.org/10.1007/978-981-13-9073-9_22

[8] Chan, J. F. W., Yuan, S., Chu, H., Sridhar, S., & Yuen, K. Y. (2024). COVID-19 drug discovery and treatment options. *Nature Reviews Microbiology*, 1-17.https://doi.org/10.1038/s41579-024-01036-y

[9] Chawla, A., Wang, C., Patton, C., Murray, M., Punekar, Y., de Ruiter, A., & Steinhart, C. (2018). A Review of Long-Term Toxicity of Antiretroviral Treatment Regimens and Implications for an Aging Population. *Infectious diseases and therapy*, *7*(2), 183–195. https://doi.org/10.1007/s40121-018-0201-6

[10] Chou, T. C., Maggirwar, N. S., & Marsden, M. D. (2024). HIV Persistence, Latency, and Cure Approaches: Where Are We Now?. *Viruses*, *16*(7), 1163. https://doi.org/10.3390/v16071163

[11] Churchill, M. J., Deeks, S. G., Margolis, D. M., Siliciano, R. F., & Swanstrom, R. (2016). HIV reservoirs: what, where and how to target them. *Nature reviews. Microbiology*, *14*(1), 55–60. https://doi.org/10.1038/nrmicro.2015.5

[12] Clutter, D. S., Jordan, M. R., Bertagnolio, S., & Shafer, R. W. (2016). HIV-1 drug resistance and resistance testing. *Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases*, *46*, 292–307. https://doi.org/10.1016/j.meegid.2016.08.031

[13] Cohen J. I. (2020). Herpesvirus latency. *The Journal of clinical investigation*, *130*(7), 3361–3369. https://doi.org/10.1172/JCI136225

[14] Dawoud, D. M., & Soliman, K. Y. (2020). Cost-Effectiveness of Antiviral Treatments for Pandemics and Outbreaks of Respiratory Illnesses, Including COVID-19: A Systematic Review of Published Economic Evaluations. *Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research*, *23*(11), 1409–1422. https://doi.org/10.1016/j.jval.2020.07.002

[15] Douglass, C. H., Pedrana, A., Lazarus, J. V., 't Hoen, E. F. M., Hammad, R., Leite, R. B., Hill, A., & Hellard, M. (2018). Pathways to ensure universal and affordable access to hepatitis C treatment. *BMC medicine*, *16*(1), 175. https://doi.org/10.1186/s12916-018-1162-z

[16] Du, S., Hu, X., Menéndez-Arias, L., Zhan, P., & Liu, X. (2024). Target-based drug design strategies to overcome resistance to antiviral agents: opportunities and challenges. *Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy*, *73*, 101053. https://doi.org/10.1016/j.drup.2024.101053

[17] Duffy S. (2018). Why are RNA virus mutation rates so damn high?. *PLoS biology*, *16*(8), e3000003. https://doi.org/10.1371/journal.pbio.3000003

[18] Feng J. Y. (2018). Addressing the selectivity and toxicity of antiviral nucleosides. *Antiviral chemistry & chemotherapy*, *26*, 2040206618758524. https://doi.org/10.1177/2040206618758524

[19] Fitzsimmons, W. J., Woods, R. J., McCrone, J. T., Woodman, A., Arnold, J. J., Yennawar, M., Evans, R., Cameron, C. E., & Lauring, A. S. (2018). A speed-fidelity trade-off determines the mutation rate and virulence of an RNA virus. *PLoS biology*, *16*(6), e2006459. https://doi.org/10.1371/journal.pbio.2006459

[20] Formiga, F. R., Leblanc, R., de Souza Rebouças, J., Farias, L. P., de Oliveira, R. N., & Pena, L. (2021). Ivermectin: an award-winning drug with expected antiviral activity against COVID-19. *Journal of controlled release : official journal of the Controlled Release Society*, *329*, 758–761. https://doi.org/10.1016/j.jconrel.2020.10.009

[21] Gao, Y., Zhao, Y., Guyatt, G., Fowler, R., Kojan, R., Ge, L., Tian, J., Collaborators, & Hao, Q. (2022). Effects of therapies for Ebola virus disease: a systematic review and network meta-analysis. *The Lancet. Microbe*, *3*(9), e683–e692. https://doi.org/10.1016/S2666-5247(22)00123-9

[22] Geraghty, R. J., Aliota, M. T., & Bonnac, L. F. (2021). Broad-Spectrum Antiviral Strategies and Nucleoside Analogues. *Viruses*, *13*(4), 667. https://doi.org/10.3390/v13040667

[23] Gohar, M., Rehman, I. U., Ullah, A., Khan, M. A., Yasmin, H., Ahmad, J., Butt, S., & Ahmad, A. (2023). Phylogenetic Analysis and Emerging Drug Resistance against Different Nucleoside Analogues in Hepatitis B Virus Positive Patients. *Microorganisms*, *11*(11), 2622. https://doi.org/10.3390/microorganisms11112622

[24] Goto, A., Rodriguez-Esteban, R., Scharf, S. H., & Morris, G. M. (2022). Understanding the genetics of viral drug resistance by integrating clinical data and mining of the scientific literature. *Scientific reports*, *12*(1), 14476. https://doi.org/10.1038/s41598-022-17746-3

[25] Gozzo, L., Caraci, F., & Drago, F. (2022). Bioequivalence, Drugs with Narrow Therapeutic Index and The Phenomenon of Biocreep: A Critical Analysis of the System for Generic Substitution. *Healthcare (Basel, Switzerland)*, *10*(8), 1392. https://doi.org/10.3390/healthcare10081392

[26] Habet S. (2021). Narrow Therapeutic Index drugs: clinical pharmacology perspective. *The Journal of pharmacy and pharmacology*, *73*(10), 1285–1291. https://doi.org/10.1093/jpp/rgab102

[27] Harada, N., Shibata, W., Koh, H., Takashita, E., Fujisaki, S., Okamura, H., Nanno, S., Yamada, K., Nakamae, H., Hino, M., & Kakeya, H. (2020). Successful treatment with baloxavir marboxil of a patient with peramivir-resistant influenza A/H3N2 with a dual E119D/R292K substitution

after allogeneic hematopoietic cell transplantation: a case report. *BMC infectious diseases*, *20*(1), 478. https://doi.org/10.1186/s12879-020-05205-1

[28] Hoffman, S. A., & Maldonado, Y. A. (2024). Emerging and re-emerging pediatric viral diseases: a continuing global challenge. *Pediatric research*, *95*(2), 480–487. https://doi.org/10.1038/s41390-023-02878-7

[29] Hughes, D., & Andersson, D. I. (2015). Evolutionary consequences of drug resistance: shared principles across diverse targets and organisms. *Nature reviews. Genetics*, *16*(8), 459–471. https://doi.org/10.1038/nrg3922

[30] Huntjens, D. W., Dijkstra, J. A., Verwiel, L. N., Slijkhuis, M., Elbers, P., Welkers, M. R. A., Veldkamp, A. I., Kuijvenhoven, M. A., de Leeuw, D. C., Abdullah-Koolmees, H., Kuipers, M. T., & Bartelink, I. H. (2023). Optimizing Antiviral Dosing for HSV and CMV Treatment in Immunocompromised Patients. *Pharmaceutics*, *15*(1), 163. https://doi.org/10.3390/pharmaceutics15010163

[31] Ianevski, A., Ahmad, S., Anunnitipat, K., Oksenych, V., Zusinaite, E., Tenson, T., Bjørås, M., & Kainov, D. E. (2022). Seven classes of antiviral agents. *Cellular and molecular life sciences : CMLS*, *79*(12), 605. https://doi.org/10.1007/s00018-022-04635-1

[32] Iketani, S., Mohri, H., Culbertson, B., Hong, S. J., Duan, Y., Luck, M. I., Annavajhala, M. K., Guo, Y., Sheng, Z., Uhlemann, A. C., Goff, S. P., Sabo, Y., Yang, H., Chavez, A., & Ho, D. D. (2023). Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir. *Nature*, *613*(7944), 558–564. https://doi.org/10.1038/s41586-022-05514-2

[33] Ip, J. D., Wing-Ho Chu, A., Chan, W. M., Cheuk-Ying Leung, R., Umer Abdullah, S. M., Sun, Y., & Kai-Wang To, K. (2023). Global prevalence of SARS-CoV-2 3CL protease mutations associated with nirmatrelvir or ensitrelvir resistance. *EBioMedicine*, *91*, 104559. https://doi.org/10.1016/j.ebiom.2023.104559

[34] Irwin, K. K., Renzette, N., Kowalik, T. F., & Jensen, J. D. (2016). Antiviral drug resistance as an adaptive process. *Virus evolution*, *2*(1), vew014. https://doi.org/10.1093/ve/vew014

[35] Iversen, P. L., Kane, C. D., Zeng, X., Panchal, R. G., Warren, T. K., Radoshitzky, S. R., Kuhn, J. H., Mudhasani, R. R., Cooper, C. L., Shurtleff, A. C., Nasar, F., Sunay, M. M., Duplantier, A. J., Eaton, B. P., Zumbrun, E. E., Bixler, S. L., Martin, S., Meinig, J. M., Chiang, C. Y., Sanchez-Lockhart, M., … Saunders, D. L. (2020). Recent successes in therapeutics for Ebola virus disease: no time for complacency. *The Lancet. Infectious diseases*, *20*(9), e231–e237. https://doi.org/10.1016/S1473-3099(20)30282-6

[36] Jamrozik, E., & Selgelid, M. J. (2020). Drug-resistant infection: Causes, consequences, and responses. *Ethics and drug resistance: Collective responsibility for global public health*, 3-18. https://doi.org/10.1007/978-3-030-27874-8

[37] Jiang, X., Vouri, S. M., Diaby, V., Lo-Ciganic, W., Parker, R., & Park, H. (2021). Health care utilization and costs associated with direct-acting antivirals for patients with substance use disorders and chronic hepatitis C. *Journal of managed care & specialty pharmacy*, *27*(10), 1388–1402. https://doi.org/10.18553/jmcp.2021.27.10.1388

[38] Jiang, X., Diaby, V., Vouri, S. M., Lo-Ciganic, W., Parker, R. L., Wang, W., Chang, S. H., Wilson, D. L., Henry, L., & Park, H. (2023). Economic Impact of Universal Hepatitis C Virus Testing for Middle-Aged Adults Who Inject Drugs. *American journal of preventive medicine*, *64*(1), 96–104. https://doi.org/10.1016/j.amepre.2022.08.016

[39] Kaplan, D. E., Serper, M., Kaushik, A., Durkin, C., Raad, A., El-Moustaid, F., Smith, N., & Yehoshua, A. (2022). Cost-effectiveness of direct-acting antivirals for chronic hepatitis C virus in the United States from a payer perspective. *Journal of managed care & specialty pharmacy*, *28*(10), 1138–1148. https://doi.org/10.18553/jmcp.2022.28.10.1138

[40] Kesselheim, A. S., Darrow, J. J., Kulldorff, M., Brown, B. L., Mitra-Majumdar, M., Lee, C. C., Moneer, O., & Avorn, J. (2021). An Overview Of Vaccine Development, Approval, And Regulation, With Implications For COVID-19. *Health affairs (Project Hope)*, *40*(1), 25–32. https://doi.org/10.1377/hlthaff.2020.01620

[41] Kim, I. J., Lanthier, P. A., Clark, M. J., De La Barrera, R. A., Tighe, M. P., Szaba, F. M., Travis, K. L., Low-Beer, T. C., Cookenham, T. S., Lanzer, K. G., Bernacki, D. T., Johnson, L. L., Schneck, A. A., Ross, C. N., Tardif, S. D., Layne-Colon, D., Mdaki, S. D., Dick, E. J., Jr, Chuba, C., Gonzalez, O., … Blackman, M. A. (2022). Efficacy of an inactivated Zika vaccine against virus infection during pregnancy in mice and marmosets. *NPJ vaccines*, *7*(1), 9. https://doi.org/10.1038/s41541-021-00426-0

[42] Kiso, M., Furusawa, Y., Uraki, R., Imai, M., Yamayoshi, S., & Kawaoka, Y. (2023). In vitro and in vivo characterization of SARS-CoV-2 strains resistant to nirmatrelvir. *Nature Communications*, *14*(1), 3952. https://doi.org/10.1038/s41467-023-39704-x

[43] Kolakowska, A., Maresca, A. F., Collins, I. J., & Cailhol, J. (2019). Update on Adverse Effects of HIV Integrase Inhibitors. *Current treatment options in infectious diseases*, *11*(4), 372–387. https://doi.org/10.1007/s40506-019-00203-7

[44] Kommandantvold, S. A., Chang, S. C., Surinach, A., Yau, V., Best, J. H., Zaraket, H., Zhou, H., Frimpter, J., & Blanchet Zumofen, M. H. (2024). Cost-Effectiveness of Baloxavir Marboxil Versus Oseltamivir or no Treatment for the Management of Influenza in the United States. *Infectious diseases and therapy*, *13*(9), 2071–2087. https://doi.org/10.1007/s40121-024-01027-9

[45] Kurt Yilmaz, N., & Schiffer, C. A. (2021). Introduction: Drug Resistance. *Chemical reviews*, *121*(6), 3235–3237. https://doi.org/10.1021/acs.chemrev.1c00118

[46] Lampejo T. (2020). Influenza and antiviral resistance: an overview. *European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology*, *39*(7), 1201–1208. https://doi.org/10.1007/s10096-020-03840-9

[47] Lee, C., Sapasap, J., LaRochelle, J., Smith, R. O., & Badowski, M. E. (2021). Antiretroviral Therapy in Children and Adolescents: A Look Into Modern Single Tablet Regimens. *The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG*, *26*(8), 783–794. https://doi.org/10.5863/1551-6776-26.8.783

[48] Li, S., Li, H., Lian, R., Xie, J., & Feng, R. (2024). New perspective of small-molecule antiviral drugs development for RNA viruses. *Virology*, *594*, 110042. https://doi.org/10.1016/j.virol.2024.110042

[49] Lieberman P. M. (2016). Epigenetics and Genetics of Viral Latency. *Cell host & microbe*, *19*(5), 619–628. https://doi.org/10.1016/j.chom.2016.04.008

[50] Lim, A. G., Aas, C. F., Çağlar, E. S., Vold, J. H., Fadnes, L. T., Vickerman, P., & Johansson, K. A. (2023). Cost-effectiveness of integrated treatment for hepatitis C virus (HCV) among people who inject drugs in Norway: An economic evaluation of the INTRO-HCV trial. *Addiction (Abingdon, England)*, *118*(12), 2424–2439. https://doi.org/10.1111/add.16305

[51] Liu, L., Liu, Y., Chen, R., Li, X., Luo, D., Zhao, Y., Li, Q., Huang, B., Wang, F. S., Liu, X., & Xu, D. (2019). Prevalence of the entecavir-resistance-inducing mutation rtA186T in a large cohort of Chinese hepatitis B virus patients. *Antiviral research*, *164*, 131–138. https://doi.org/10.1016/j.antiviral.2019.02.012

[52] Liu, Y., Zhou, Y., Li, X., Niu, M., Chen, R., Shao, J., Si, L., Luo, D., Lin, Y., Li, L., Zhang, K., Xiao, X., Xu, Z., Liu, M., Lu, M., Zoulim, F., & Xu, D. (2019). Hepatitis B virus mutation pattern rtL180M+A181C+M204V may contribute to entecavir resistance in clinical practice. *Emerging microbes & infections*, *8*(1), 354–365. https://doi.org/10.1080/22221751.2019.1584018

[53] Ma, C., Zhang, J., & Wang, J. (2016). Pharmacological Characterization of the Spectrum of Antiviral Activity and Genetic Barrier to Drug Resistance of M2-S31N Channel Blockers. *Molecular pharmacology*, *90*(3), 188–198. https://doi.org/10.1124/mol.116.105346

[54] Mafirakureva, N., Stone, J., Fraser, H., Nzomukunda, Y., Maina, A., Thiong'o, A. W., Kizito, K. W., Mucara, E. W. K., González Diaz, C. I., Musyoki, H., Mundia, B., Cherutich, P., Nyakowa, M., Lizcano, J., Chhun, N., Kurth, A., Akiyama, M. J., Waruiru, W., Bhattacharjee, P., Cleland, C., … Vickerman, P. (2022). An intensive model of care for hepatitis C virus screening and treatment with direct-acting antivirals in people who inject drugs in Nairobi, Kenya: a model-based cost-effectiveness analysis. *Addiction (Abingdon, England)*, *117*(2), 411–424. https://doi.org/10.1111/add.15630

[55] Mahajan, S., Choudhary, S., Kumar, P., & Tomar, S. (2021). Antiviral strategies targeting host factors and mechanisms obliging +ssRNA viral pathogens. *Bioorganic & medicinal chemistry*, *46*, 116356. https://doi.org/10.1016/j.bmc.2021.116356

[56] Marquez, L. K., Fleiz, C., Burgos, J. L., Cepeda, J. A., McIntosh, C., Garfein, R. S., Kiene, S. M., Brodine, S., Strathdee, S. A., & Martin, N. K. (2021). Cost-effectiveness of hepatitis C virus (HCV) elimination strategies among people who inject drugs (PWID) in Tijuana, Mexico. *Addiction (Abingdon, England)*, *116*(10), 2734–2745. https://doi.org/10.1111/add.15456

[57] Mason, S., Devincenzo, J. P., Toovey, S., Wu, J. Z., & Whitley, R. J. (2018). Comparison of antiviral resistance across acute and chronic viral infections. *Antiviral research*, *158*, 103–112. https://doi.org/10.1016/j.antiviral.2018.07.020

[58] Mazaherpour, H., Sofian, M., Farahani, E., Abdi, A., Mazaherpour, S., Bavand, A., & Ramezani, A. (2022). Comparing Outcomes of Two Antiviral Therapy Combinations among COVID-19 Patients. *BioMed research international*, *2022*, 1522426. https://doi.org/10.1155/2022/1522426

[59] Meganck, R. M., & Baric, R. S. (2021). Developing therapeutic approaches for twenty-first-century emerging infectious viral diseases. *Nature medicine*, *27*(3), 401–410. https://doi.org/10.1038/s41591-021-01282-0

[60] Musharrafieh, R., Ma, C., & Wang, J. (2020). Discovery of M2 channel blockers targeting the drug-resistant double mutants M2-S31N/L26I and M2-S31N/V27A from the influenza A viruses. *European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences*, *141*, 105124. https://doi.org/10.1016/j.ejps.2019.105124

[61] Musharrafieh, R., Ma, C., & Wang, J. (2018). Profiling the in vitro drug-resistance mechanism of influenza A viruses towards the AM2-S31N proton channel blockers. *Antiviral research*, *153*, 10–22. https://doi.org/10.1016/j.antiviral.2018.03.002

[62] Nalwanga, D., & Musiime, V. (2022). Children living with HIV: a narrative review of recent advances in pediatric HIV research and their implications for clinical practice. *Therapeutic advances in infectious disease*, *9*, 20499361221077544. https://doi.org/10.1177/20499361221077544

[63] Nemčovičová, I., Lopušná, K., Štibrániová, I., Benedetti, F., Berti, F., Felluga, F., Drioli, S., Vidali, M., Katrlík, J., Pažitná, L., Holazová, A., Blahutová, J., Lenhartová, S., Sláviková, M., Klempa, B., Ondrejovič, M., Chmelová, D., Legerská, B., Miertuš, S., Klacsová, M., … Frecer, V. (2024). Identification and evaluation of antiviral activity of novel compounds targeting SARS-CoV-2 virus by enzymatic and antiviral assays, and computational analysis. *Journal of enzyme inhibition and medicinal chemistry*, *39*(1), 2301772. https://doi.org/10.1080/14756366.2024.2301772

[64] Nie, Z., Sun, T., & Zhao, F. (2022). Safety and Efficacy of Antiviral Drugs for the Treatment of COVID-19: A Systematic Review. *Infection and drug resistance*, *15*, 4457–4466. https://doi.org/10.2147/IDR.S362946

[65] Nyberg, L. M., Kaushik, A., Smith, N., El Moustaid, F., Nyberg, A. H., Yang, S. J., Chiang, K. M., & Yehoshua, A. (2023). Real-world value of direct-acting antivirals for hepatitis C at Kaiser Permanente Southern California. *The American journal of managed care*, *29*(10), e299–e306. https://doi.org/10.37765/ajmc.2023.89444

[66] Penazzato, M., Townsend, C. L., Sam-Agudu, N. A., Ruel, T. D., Archary, M., Bekker, A., Cressey, T. R., Colbers, A., Sugandhi, N., Rojo, P., Rakhmanina, N., Watkins, M., Frigati, L., Mukui, I., Hafiz, A., Vicari, M., Capparelli, E. V., Abrams, E. J., & PADO-HIV 5 participants (2022). Advancing the prevention and treatment of HIV in children: priorities for research and development. *The lancet. HIV*, *9*(9), e658–e666. https://doi.org/10.1016/S2352-3018(22)00101-1

[67] Rogers, M. B., Song, T., Sebra, R., Greenbaum, B. D., Hamelin, M. E., Fitch, A., Twaddle, A., Cui, L., Holmes, E. C., Boivin, G., & Ghedin, E. (2015). Intrahost dynamics of antiviral resistance in influenza A virus reflect complex patterns of segment linkage, reassortment, and natural selection. *mBio*, *6*(2), e02464-14. https://doi.org/10.1128/mBio.02464-14

[68] Shao, J., Liu, Y., Liu, L. M., Chen, R., Zhao, L., Zhou, Y., Li, L., Li, X., Li, J., & Xu, D. (2021). Multiple drug-resistant HBV mutation may contribute to poor response of adefovir + entecavir in entecavir-resistant patients. *Journal of infection in developing countries*, *15*(1), 131–140. https://doi.org/10.3855/jidc.12643

[69] Shook, B. C., & Lin, K. (2017). Recent Advances in Developing Antiviral Therapies for Respiratory Syncytial Virus. *Topics in current chemistry (Cham)*, *375*(2), 40. https://doi.org/10.1007/s41061-017-0129-4

[70] Shyr, Z. A., Cheng, Y. S., Lo, D. C., & Zheng, W. (2021). Drug combination therapy for emerging viral diseases. *Drug discovery today*, *26*(10), 2367–2376. https://doi.org/10.1016/j.drudis.2021.05.008

[71] Smith E. C. (2017). The not-so-infinite malleability of RNA viruses: Viral and cellular determinants of RNA virus mutation rates. *PLoS pathogens*, *13*(4), e1006254. https://doi.org/10.1371/journal.ppat.1006254

[72] Speck, S. H., & Ganem, D. (2010). Viral latency and its regulation: lessons from the gamma-herpesviruses. *Cell host & microbe*, *8*(1), 100–115. https://doi.org/10.1016/j.chom.2010.06.014

[73] Tai, C. M., & Yu, M. L. (2024). Hepatitis C virus micro-elimination in people who inject drugs: Challenges and chance in Taiwan and worldwide. *The Kaohsiung journal of medical sciences*, *40*(2), 112–118. https://doi.org/10.1002/kjm2.12788

[74] Tamargo, J., Le Heuzey, J. Y., & Mabo, P. (2015). Narrow therapeutic index drugs: a clinical pharmacological consideration to flecainide. *European journal of clinical pharmacology*, *71*(5), 549–567. https://doi.org/10.1007/s00228-015-1832-0

[75] Taroncher-Oldenburg, G., Müller, C., Obermann, W., Ziebuhr, J., Hartmann, R. K., & Grünweller, A. (2021). Targeting the DEAD-Box RNA Helicase eIF4A with Rocaglates-A Pan-Antiviral Strategy for Minimizing the Impact of Future RNA Virus Pandemics. *Microorganisms*, *9*(3), 540. https://doi.org/10.3390/microorganisms9030540

[76] Tompa, D. R., Immanuel, A., Srikanth, S., & Kadhirvel, S. (2021). Trends and strategies to combat viral infections: A review on FDA approved antiviral drugs. *International journal of biological macromolecules*, *172*, 524–541. https://doi.org/10.1016/j.ijbiomac.2021.01.076

[77] Treisman, G. J., & Soudry, O. (2016). Neuropsychiatric Effects of HIV Antiviral Medications. *Drug safety*, *39*(10), 945–957. https://doi.org/10.1007/s40264-016-0440-y

[78] Valencia Deray, K. G., Danziger-Isakov, L. A., & Downes, K. J. (2024). Current and Emerging Antiviral Agents in the Prevention and Treatment of Cytomegalovirus in Pediatric Transplant Recipients. *Journal of the Pediatric Infectious Diseases Society*, *13*(Supplement_1), S14–S21. https://doi.org/10.1093/jpids/piad059

[79] Vincenti, D., Piselli, P., Solmone, M., D'Offizi, G., Capobianchi, M. R., & Menzo, S. (2017). Evolutionary trends of resistance mutational patterns of HBV reverse transcriptase over years (2002-2012) of different treatment regimens: The legacy of lamivudine/adefovir combination treatment. *Antiviral research*, *143*, 62–68. https://doi.org/10.1016/j.antiviral.2017.03.008

[80] Wang H. (2024). Practical updates in clinical antiviral resistance testing. *Journal of clinical microbiology*, *62*(8), e0072823. https://doi.org/10.1128/jcm.00728-23

[81] Wang, M. L., & Tang, H. (2016). Nucleos(t)ide analogues causes HBV S gene mutations and carcinogenesis. *Hepatobiliary & pancreatic diseases international : HBPD INT*, *15*(6), 579–586. https://doi.org/10.1016/s1499-3872(16)60064-4

[82] Wang, X., Tai, W., Zhang, X., Zhou, Y., Du, L., & Shen, C. (2019). Effects of Adjuvants on the Immunogenicity and Efficacy of a Zika Virus Envelope Domain III Subunit Vaccine. *Vaccines*, *7*(4), 161. https://doi.org/10.3390/vaccines7040161

[83] Wang, Y., Hu, Y., Xu, S., Zhang, Y., Musharrafieh, R., Hau, R. K., Ma, C., & Wang, J. (2018). In Vitro Pharmacokinetic Optimizations of AM2-S31N Channel Blockers Led to the Discovery of Slow-Binding Inhibitors with Potent Antiviral Activity against Drug-Resistant Influenza A Viruses. *Journal of medicinal chemistry*, *61*(3), 1074–1085. https://doi.org/10.1021/acs.jmedchem.7b01536

[84] Wyles, D. L., & Luetkemeyer, A. F. (2017). Understanding Hepatitis C Virus Drug Resistance: Clinical Implications for Current and Future Regimens. *Topics in antiviral medicine*, *25*(3), 103–109.

[85] Xiang, Q., Ju, H., Li, Q., Mei, S. C., Chen, D., Choi, Y. B., & Nicholas, J. (2018). Human Herpesvirus 8 Interferon Regulatory Factors 1 and 3 Mediate Replication and Latency Activities via Interactions with USP7 Deubiquitinase. *Journal of virology*, *92*(7), e02003-17. https://doi.org/10.1128/JVI.02003-17

[86] Yamamoto, C., Taniguchi, M., Furukawa, K., Inaba, T., Niiyama, Y., Ide, D., Mizutani, S., Kuroda, J., Tanino, Y., Nishioka, K., Watanabe, Y., Takayama, K., Nakaya, T., & Nukui, Y. (2024). Nirmatrelvir Resistance in an Immunocompromised Patient with Persistent Coronavirus Disease 2019. *Viruses*, *16*(5), 718. https://doi.org/10.3390/v16050718

[87] Zala, D., Mosweu, I., Critchlow, S., Romeo, R., & McCrone, P. (2020). Costing the COVID-19 Pandemic: An Exploratory Economic Evaluation of Hypothetical Suppression Policy in the United Kingdom. *Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research*, *23*(11), 1432–1437. https://doi.org/10.1016/j.jval.2020.07.001

[88] Zareifopoulos, N., Lagadinou, M., Karela, A., Kyriakopoulou, O., & Velissaris, D. (2020). Neuropsychiatric Effects of Antiviral Drugs. *Cureus*, *12*(8), e9536. https://doi.org/10.7759/cureus.9536

[89] Zhang, H., Quadeer, A. A., & McKay, M. R. (2023). Direct-acting antiviral resistance of Hepatitis C virus is promoted by epistasis. *Nature communications*, *14*(1), 7457. https://doi.org/10.1038/s41467-023-42550-6

[90] Zhang, X., Chen, X., Wei, M., Zhang, C., Xu, T., Liu, L., & Xu, Z. (2019). Potential resistant mutations within HBV reverse transcriptase sequences in nucleos(t)ide analogues-experienced patients with hepatitis B virus infection. *Scientific reports*, *9*(1), 8078. https://doi.org/10.1038/s41598-019-44604-6

[91] Zhu, Y., Yurgelonis, I., Noell, S., Yang, Q., Guan, S., Li, Z., Hao, L., Rothan, H., Rai, D. K., McMonagle, P., Baniecki, M. L., Greasley, S. E., Plotnikova, O., Lee, J., Nicki, J. A., Ferre, R., Byrnes, L. J., Liu, W., Craig, T. K., Steppan, C. M., … Cardin, R. D. (2024). In vitro selection and analysis of SARS-CoV-2 nirmatrelvir resistance mutations contributing to clinical virus resistance surveillance. *Science advances*, *10*(30), eadl4013. https://doi.org/10.1126/sciadv.adl4013